NR3C1 and Anxiety: To this end, we investigated whether treatment with MDMA, when administered adjunctively to trauma-cue (memory reactivation) or alone, would (1.1) reduce predator-scent stress (PSS)-induced anxiety-like responses and hyperarousal; (1.2) shift the prevalence rates of extreme responders (PTSD-phenotype) towards partial and/or minimal responders; and (1.3) affect the PSS-induced morphological damage in the hippocampus and basolateral amygdala (BLA) and (2) to assess whether glucocorticoid receptors (GR) are involved in the therapeutic effects of MDMA treatment paired with a trauma-cue.